Zymeworks logo

Zymeworks share price today

(ZYME)

Zymeworks share price is $14.46 & ₹1,240.81 as on 7 Jan 2025, 2.30 'hrs' IST

$14.46

▲

-0.55

(-3.66%)

Market is closed - opens 8 PM, 07 Jan 2025

View live Zymeworks share price in Dollar and Rupees. Guide to invest in Zymeworks stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Zymeworks, along with analyst recommendations, forecasts, and comprehensive financials.

Zymeworks share price movements

  • Today's Low: $14.46
    Today's High: $15.13

    Day's Volatility :4.43%

  • 52 Weeks Low: $7.97
    52 Weeks High: $17.70

    52 Weeks Volatility :54.97%

Zymeworks Returns

PeriodZymeworks IncRussel 2000Index (Russel 2000)
3 Months
19.79%
0.0%
0.0%
6 Months
60.53%
0.0%
0.0%
1 Year
30.07%
0.0%
0.0%
3 Years
5.11%
-19.8%
-19.8%

Zymeworks Key Statistics

in dollars & INR

Previous Close
$15.01
Open
$15.25
Today's High
$15.13
Today's Low
$14.46
Market Capitalization
$1.0B
Today's Volume
$843.9K
52 Week High
$17.7
52 Week Low
$7.97
Revenue TTM
$62.2M
EBITDA
$-114.7M
Earnings Per Share (EPS)
$-1.49
Profit Margin
-182.75%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-28.73%

How to invest in Zymeworks from India?

It is very easy for Indian residents to invest directly in Zymeworks from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Zymeworks stock in both Indian Rupees (INR) and US Dollars (USD). Search for Zymeworks or ZYME on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Zymeworks or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Zymeworks shares which would translate to 0.059 fractional shares of Zymeworks as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Zymeworks, in just a few clicks!

Returns in Zymeworks for Indian investors in Rupees

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Zymeworks investment value today

Current value as on today

₹1,28,526

Returns

₹28,526

(+28.53%)

Returns from Zymeworks Stock

₹25,303 (+25.3%)

Dollar Returns

₹3,223 (+3.22%)

Indian investors sentiment towards Zymeworks

61%

Period: Oct 8, 2024 to Jan 6, 2025. Change in 30 Days versus previous period

Search volume for Zymeworks on INDmoney from India has grown in the last 30 days as on Jan 7, 2025. 61% more investors are searching Zymeworks in the last 30 days versus the previous period.

Global Institutional Holdings in Zymeworks

  • EcoR1 Capital, LLC

    19.51%

  • Morgan Stanley - Brokerage Accounts

    7.41%

  • Redmile Group, LLC

    7.41%

  • Bvf Inc

    6.69%

  • BlackRock Inc

    6.09%

  • Rubric Capital Management LP

    5.69%

Analyst Recommendation on Zymeworks

Buy

    71%Buy

    28%Hold

    0%Sell

Based on 14 Wall street analysts offering stock ratings for Zymeworks(by analysts ranked 0 to 5 stars)

Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
11
Hold
4
4
4
Sell
0
0
0

Analyst Forecast on Zymeworks

What analysts predicted

Upside of 37.31%

Current:

$14.46

Target:

$19.86

Insights on Zymeworks

  • Price Movement

    In the last 6 months, ZYME stock has moved up by 69.0%

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 19.24M → 16.0M (in $), with an average decrease of 16.9% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -37.68M → -29.85M (in $), with an average increase of 26.3% per quarter

  • ZYME vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 55.2% return, outperforming this stock by 48.5%

Zymeworks Financials in INR & Dollars

FY18Y/Y Change
Revenue
$53.0M
↑ 2.43%
Net Income
$-36.6M
↑ 251.3%
Net Profit Margin
-68.95%
↓ 48.85%
FY19Y/Y Change
Revenue
$29.5M
↓ 44.28%
Net Income
$-145.4M
↑ 297.85%
Net Profit Margin
-492.27%
↓ 423.32%
FY20Y/Y Change
Revenue
$39.0M
↑ 31.84%
Net Income
$-180.6M
↑ 24.14%
Net Profit Margin
-463.54%
↑ 28.73%
FY21Y/Y Change
Revenue
$26.7M
↓ 31.5%
Net Income
$-211.8M
↑ 17.33%
Net Profit Margin
-794.01%
↓ 330.47%
FY22Y/Y Change
Revenue
$412.5M
↑ 1446.03%
Net Income
$124.3M
↓ 158.69%
Net Profit Margin
30.14%
↑ 824.15%
FY23Y/Y Change
Revenue
$76.0M
↓ 81.57%
Net Income
$-118.7M
↓ 195.44%
Net Profit Margin
-156.13%
↓ 186.27%
Q2 FY23Q/Q Change
Revenue
$7.0M
↓ 80.32%
Net Income
$-51.2M
↑ 110.04%
Net Profit Margin
-730.53%
↓ 662.08%
Q3 FY23Q/Q Change
Revenue
$16.5M
↑ 135.73%
Net Income
$-28.7M
↓ 43.92%
Net Profit Margin
-173.8%
↑ 556.73%
Q4 FY23Q/Q Change
Revenue
$16.9M
↑ 2.54%
Net Income
$-14.5M
↓ 49.52%
Net Profit Margin
-85.56%
↑ 88.24%
Q1 FY24Q/Q Change
Revenue
$10.0M
↓ 40.74%
Net Income
$-31.7M
↑ 118.57%
Net Profit Margin
-315.58%
↓ 230.02%
Q2 FY24Q/Q Change
Revenue
$19.2M
↑ 91.85%
Net Income
$-37.7M
↑ 19.06%
Net Profit Margin
-195.84%
↑ 119.74%
Q3 FY24Q/Q Change
Revenue
$16.0M
↓ 16.85%
Net Income
$-29.9M
↓ 20.79%
Net Profit Margin
-186.56%
↑ 9.28%
FY18Y/Y Change
Profit
$53.0M
↑ 399.33%
FY19Y/Y Change
Profit
$-87.6M
↓ 265.13%
FY20Y/Y Change
Profit
$39.0M
↓ 144.49%
FY21Y/Y Change
Profit
$26.7M
↓ 31.5%
FY22Y/Y Change
Profit
$412.5M
↑ 1446.03%
FY23Y/Y Change
Profit
$-67.0M
↓ 116.24%
Q2 FY23Q/Q Change
Profit
$-32.4M
↑ 229.5%
Q3 FY23Q/Q Change
Profit
$-16.4M
↓ 49.28%
Q4 FY23Q/Q Change
Profit
$-8.3M
↓ 49.51%
Q1 FY24Q/Q Change
Profit
$-22.7M
↑ 173.67%
Q2 FY24Q/Q Change
Profit
$16.7M
↓ 173.59%
Q3 FY24Q/Q Change
Profit
$13.3M
↓ 20.2%
FY18Y/Y Change
Operating Cash Flow
$24.2M
↑ 10939.73%
Investing Cash Flow
$-109.0M
↑ 253.04%
Financing Cash Flow
$91.4M
↑ 83.04%
FY19Y/Y Change
Operating Cash Flow
$-81.9M
↓ 438.56%
Investing Cash Flow
$-25.6M
↓ 76.53%
Financing Cash Flow
$193.7M
↑ 111.81%
FY20Y/Y Change
Operating Cash Flow
$-151.4M
↑ 84.97%
Investing Cash Flow
$-43.4M
↑ 69.74%
Financing Cash Flow
$309.0M
↑ 59.55%
FY21Y/Y Change
Operating Cash Flow
$-192.5M
↑ 27.11%
Investing Cash Flow
$144.6M
↓ 432.86%
Financing Cash Flow
$8.0M
↓ 97.41%
FY22Y/Y Change
Operating Cash Flow
$144.1M
↓ 174.88%
Investing Cash Flow
$-53.8M
↓ 137.24%
Financing Cash Flow
$108.6M
↑ 1255.41%
Q2 FY23Q/Q Change
Operating Cash Flow
$-6.4M
↓ 92.31%
Investing Cash Flow
$-60.7M
↓ 56.1%
Financing Cash Flow
$27.6M
↑ 1488.15%
Q3 FY23Q/Q Change
Operating Cash Flow
$-42.7M
↑ 566.78%
Investing Cash Flow
$-7.0M
↓ 88.43%
Financing Cash Flow
$1.9M
↓ 93.13%

Zymeworks Technicals Summary

Sell

Neutral

Buy

Zymeworks is currently in a neutral trading position according to technical analysis indicators.

Zymeworks Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Zymeworks Inc
Zymeworks Inc
14.23%
60.53%
30.07%
5.11%
-53.15%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-8.86%
-31.87%
-20.46%
15.59%
87.28%
Biontech Se
Biontech Se
-4.16%
43.82%
3.49%
-49.66%
167.6%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-8.45%
-8.03%
19.03%
56.02%
98.44%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-14.11%
-16.23%
-2.87%
81.78%
76.8%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Zymeworks Inc
Zymeworks Inc
3.56
NA
0.0
-1.44
-0.29
-0.15
NA
5.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
17.61
17.61
1.06
45.07
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-3.11
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.19
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.06
0.51
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Zymeworks Inc
Zymeworks Inc
Buy
$1.0B
-53.15%
3.56
-182.75%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$78.3B
87.28%
17.61
33.61%
Biontech Se
Biontech Se
Buy
$27.3B
167.6%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$30.4B
98.44%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$103.7B
76.8%
32.84
-4.51%

About Zymeworks

zymeworks is a privately held biotherapeutics company that is developing best-in-class azymetric™ bi specific antibodies and antibody drug conjugates for the treatment of oncology, autoimmunity and inflammatory diseases. the company’s novel azymetric™ and albucore™ platforms, and its proprietary zymecad™ structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications. zymeworks is focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations. more information on zymeworks can be found at www.zymeworks.com.
Organization
Zymeworks
Employees
294
CEO
Mr. Kenneth H. Galbraith C.A.
Industry
Health Technology

Management People of Zymeworks

NameTitle
Mr. Kenneth H. Galbraith C.A.
Chairman of the Board, CEO & President
Dr. Paul A. Moore Ph.D.
Chief Scientific Officer
Ms. Leone D. Patterson CPA, M.B.A.
Executive VP and Chief Business & Financial Officer
Mr. Mark Hollywood
Executive VP and Head of Technical & Manufacturing Operations
Ms. Shrinal Inamdar
Director of Investor Relations
Mr. Daniel Dex J.D., Ph.D.
Senior VP, Corporate Secretary & General Counsel
Diana Papove
Senior Manager of Corporate Communications
Dr. Lindsey Foulkes B.Sc., Ph.D.
Vice President of Corporate Development
Ms. Laura O'Connor
Vice President of Human Resources & DEI
Dr. Jeffrey Smith M.D.
Executive VP & Chief Medical Officer

Important FAQs about investing in Zymeworks from India :

What is Zymeworks share price today?

Zymeworks share price today stands at $14.46, Open: $15.25 ; Previous Close: $15.01 ; High: $15.13 ; Low: $14.46 ; 52 Week High: $17.70 ; 52 Week Low: $7.97. The stock opens at $15.25, after a previous close of $15.01. The stock reached a daily high of $15.13 and a low of $14.46, with a 52-week high of $17.70 and a 52-week low of $7.97.

Can Indians buy Zymeworks shares?

Yes, Indians can invest in the Zymeworks (ZYME) from India.

With INDmoney, you can buy Zymeworks at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Zymeworks at zero transaction cost.

How can I buy Zymeworks shares from India?

It is very easy to buy Zymeworks from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Zymeworks be purchased?

Yes, you can buy fractional shares of Zymeworks with INDmoney app.

What are the documents required to start investing in Zymeworks stocks?

To start investing in Zymeworks, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Zymeworks

Today’s highest price of Zymeworks (ZYME) is $15.13.

Today’s lowest price of Zymeworks (ZYME) is $14.46.

What is today's market capitalisation of Zymeworks

Today's market capitalisation of Zymeworks ZYME is 1.0B

What is the 52 Week High and Low Range of Zymeworks

  • 52 Week High

    $17.70

  • 52 Week Low

    $7.97

What are the historical returns of Zymeworks?

  • 1 Month Returns

    14.23%

  • 3 Months Returns

    60.53%

  • 1 Year Returns

    30.07%

  • 5 Years Returns

    -53.15%

Who is the Chief Executive Officer (CEO) of Zymeworks

Mr. Kenneth H. Galbraith C.A. is the current Chief Executive Officer (CEO) of Zymeworks.